PTO JUN 09 2006 PATENT & TRADEMARK OFFICE

PTO/SB/08a Substitute for Form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				Application Number	10/533,158
				Filing Date	April 28, 2005
				First Named	Akira NAKAGAWA
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket	7388/84325

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Kawamoto et al., Association Between Favorable Neuroblastoma and High Expression of the Novel Metalloproteinase Gene, *nbla*3145/XCE, Cloned by Differential Screening of the Full-Length-Enriched Oligo-Capping Neuroblastoma cDNA Libraries, Medicinal and Pediatric Oncology, 35:628-631 (2000)	
		Islam et al., High Expression of *Survivin*, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma, Oncogene, 19:617-623 (Feb. 3, 2000)	
		Aoyama et al., High Expression of Human RIM Gene in neuroblastomas with favorable biologies, 31st Annual Meeting of the Society for Neuroscience in San Diego, CA Nov. 10-15, 2001, Society for Neuroscience Abstracts, 27:715 (2001)	
		Tang et al., Implications fo EPHB6, EFB2, and EFNB3 expressions in human neuroblastoma, Proceedings of the National Academy of Sciences of the United States of America, 97:10936-10941 (Sept. 26, 2000)	
		Homo Sapiens BAC Clone RP11-650J17 from 4, complete sequence, Database EMBL [OnLine], EBI Accession No. EM_PRO:AC093879 (Sept. 11, 2001)	

Examiner Signature		Date Considered	12·21·07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a
Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/533,[illegible]
Filing Date	April 28, 2005
First Named	Akira NAKAGAWA
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket	7388/84325

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
[illegible]		US-20030207286A1	11-06-2003	Nakagawara et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
[illegible]		WO 01/66719 A1	09-13-2001	Chiba-Prefecture		
[illegible]		WO 01/66733 A1	09-13-2001	Chiba-Prefecture		

Examiner Signature	[signature]	Date Considered	7.21.07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a Substitute for Form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				Application Number	10/533,158
				Filing Date	April 28, 2005
				First Named	Akira NAKAGAWA
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket	7388/84325

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Akira NAKAGAWARA, "The gene which controls biology of neuroblastoma", Japanese Journal of Pediatric Medicine, Vol. 30, No. 2, 1998-2, pp. 143-148.	
		"Sounding board, regression of neuroblastoma IV-S: a genetic hypothesis", The New England Journal of Medicine, May 29, 1980	
		Akira NAKAGAWARA, "Topical topic, the NGF story and neuroblastoma", Medical and Pediatric Oncology, 31:113-115 (1998), 1998 Wiley-Liss, Inc.	
		"Expression and prognosis of TRK family receptor in neuroblastoma", Shoni Geka (Pediatric Surgery), Vol. 29, No. 3, 1997, pp. 425-432	
		"Genetic events in neuroblastoma", Molecular Medicine, Vol. 36, No. 4, 1999, pp. 366-372.	
		EGGERT, A. et al., "High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas", Clinical Cancer Research, Vol. 6, 1900-1908, May 2000	
		GALLEGO, S. et al., "Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma", Anticancer Research, Vol. 18, pages 1211-1216 (1998)	
		S. YAMANE, "Gene expression of tumor rejection antigens recognized by cytolytic T lymphocytes in neuroblastoma-related tumors", Journal of Kyoto Prefectual University of Medicine, Vol. 108, No. 3, pp. 381-388 (1999)	
		The Sanger Centre, et al., "Toward a complete human genome sequence", Genome Research, Vol. 8, pp. 1097-1108 (1998)	

Examiner Signature		Date Considered	7.21.07